Niagen Bioscience (NAGE) Net Cash Flow Growth (1y) (2012 - 2026)
Niagen Bioscience (NAGE) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Niagen Bioscience |
280.11 Mn |
213.56 Mn |
19.98 Mn |
-83.93% |
| Date | Value |
|---|
| Mar 31, 2026 |
-83.93% |
| Dec 31, 2025 |
-95.94% |
| Sep 30, 2025 |
-14.71% |
| Jun 30, 2025 |
1,407.81% |
| Mar 31, 2025 |
4,465.00% |
| Dec 31, 2024 |
2,121.38% |
| Sep 30, 2024 |
1,129.70% |
| Jun 30, 2024 |
-90.20% |
| Mar 31, 2024 |
-91.11% |
| Dec 31, 2023 |
-92.31% |
| Sep 30, 2023 |
109.63% |
| Jun 30, 2023 |
183.27% |
| Mar 31, 2023 |
137.37% |
| Dec 31, 2022 |
247.02% |
| Sep 30, 2022 |
32.88% |
| Jun 30, 2022 |
33.69% |
| Mar 31, 2022 |
-125.81% |
| Dec 31, 2021 |
-500.57% |
| Sep 30, 2021 |
-66.35% |
| Jun 30, 2021 |
-211.95% |
